Search our Database of Scientific Publications and Authors

I’m looking for a

    1764 results match your criteria Hidradenitis Suppurativa

    1 OF 36

    Hormonal therapies for hidradenitis suppurativa: Review.
    Dermatol Online J 2017 Nov 12;23(10). Epub 2017 Nov 12.
    Department of Dermatology, University of California, Davis, Sacramento, California, Department of Biological Sciences, California State University-Sacramento, Sacramento, California.
    Hidradenitis suppurativa is a recurrent inflammatory skin condition characterized by abscesses and boils, predominantly in the groin, armpit, and buttocks areas. HS is not a life-threatening condition, but severely impairs quality of life in those affected. Finding a successful treatment approach for HS has been challenging, in part because of the lack of a gold-standard treatment method, limited research-based information, and the nature of clinical variation in the disease. Read More

    The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa.
    Dermatol Online J 2017 Jul 15;23(7). Epub 2017 Jul 15.
    Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
    Hidradenitis suppurativa is a chronic inflammatory skin condition affecting primarily the axillary, perianal, and inguinal areas. Patients with hidradenitis suppurativa present with occlusion and subsequent rupture of follicular ducts, profound abscesses, fistulae, odorous discharge, fibrosis, and scar formation, causing significant morbidity. Knowledge of the pathogenesis of hidradenitis suppurativa is limited and treatment with antimicrobial drugs, immunosuppressants, and surgical procedures have shown varying results. Read More

    Association of Hidradenitis Suppurativa With Body Image.
    JAMA Dermatol 2018 Feb 21. Epub 2018 Feb 21.
    Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, Berlin, Germany.
    Importance: Hidradenitis suppurativa (HS) leads to disfigurement and painful eruptions in terminal hair follicles of the intertriginous skin, mainly of axillary, genitofemoral, and perianal sites. It is associated with an excessive impairment of quality of life, psychiatric disorders, and sexual distress. Body image impairment has been linked to depression and anxiety and has been described for some dermatologic disorders but has not yet been investigated in patients with HS. Read More

    Evaluation of the mobility of the shoulder and quality of life after perforator flaps for recalcitrant axillary hidradenitis.
    Ann Chir Plast Esthet 2018 Feb 13. Epub 2018 Feb 13.
    Department of plastic, aesthetic and reconstructive surgery, hospital Tenon, 4, rue de la Chine, 75020 Paris, France.
    Background: Hidradenitis suppurativa is a very debilitating disease, treated by antibiotics and excision. The reconstruction is usually done by secondary wound healing and/or split-thichness skin graft. The aim of this study was to evaluate the reconstruction of the axilla with local perforator flaps as a single stage surgical treatment. Read More

    Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine.
    BMJ Open 2018 02 8;8(2):e018166. Epub 2018 Feb 8.
    Focused Research Unit for Molecular Diagnostic and Clinical Research, IRS-Center Sonderjylland, Hospital of Southern Jutland, Aabenraa, Denmark.
    Introduction: Chronic inflammatory diseases (CIDs) are frequently treated with biological medications, specifically tumour necrosis factor inhibitors (TNFi)). These medications inhibit the pro-inflammatory molecule TNF alpha, which has been strongly implicated in the aetiology of these diseases. Up to one-third of patients do not, however, respond to biologics, and lifestyle factors are assumed to affect treatment outcomes. Read More

    The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014.
    Int J Dermatol 2018 Feb 12. Epub 2018 Feb 12.
    Department of Medicine, Icahn School of Medicine at Mount Sinai West, New York, NY, USA.
    Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that significantly affects the patient's quality of life. Multiple studies have shown a strong association between HS and inflammatory bowel disease (IBD). Our primary goal was to explore the in-hospital burden of HS on patients with IBD. Read More

    Patients affected by Dent disease 2 could be predisposed to hidradenitis suppurativa.
    J Eur Acad Dermatol Venereol 2018 Feb 11. Epub 2018 Feb 11.
    Department of Woman, Child and of General and Specialized Surgery, Università degli Studi della Campania "Luigi Vanvitelli", Via Luigi De Crecchio 2, 80138, Napoli, Italy.
    Dent disease 2 (DD2) is a rare X-Linked disorder characterized by proximal tubule dysfunction. It is considered as mild variant of Lowe Syndrome (LS) and both conditions are secondary to OCRL1 gene mutations.Mutations in this gene drastically reduce (<10%) inositol polyphosphate 5-phosphatase (OCRL1) activity. Read More

    A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa.
    JAMA Dermatol 2018 Feb 7. Epub 2018 Feb 7.
    Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany.
    Importance: The variation in both clinical appearance and responses to diverse treatment options emphasize the importance of an accurate, clinically relevant, yet easy-to-use scoring system in hidradenitis suppurativa.

    Objective: To propose and provide validation data for the newly designed Severity Assessment of Hidradenitis Suppurativa score.

    Design, Setting, And Participants: We prospectively assessed disease severity using Hurley staging and the modified Hidradenitis Suppurativa Score in 355 patients referred to Ruhr-University Bochum Department of Dermatology between March 2016 and June 2017. Read More

    Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?
    Br J Dermatol 2018 Feb 6. Epub 2018 Feb 6.
    4th Department of Internal Medicine, University of Athens, Medical School, Greece.
    Objective: Despite the heavy purulence observed in hidradenitis suppurativa (HS), kinetics of complement anaphylatoxins acting to prime chemotaxis of neutrophils has never been studied. Complement activation was explored in HS.

    Methods: Circulating concentrations of complement factor C5a as well as of membrane attack complex C5b-9 were determined in the plasma of 54 treatment naïve patients and of 14 healthy controls as well as in the pus of seven patients. Read More

    The effect of oral clindamycin and rifampicin combination therapy in patients with hidradenitis suppurativa in Singapore.
    Clin Cosmet Investig Dermatol 2018 18;11:37-39. Epub 2018 Jan 18.
    Department of Dermatology, National Skin Centre, Singapore.
    Hidradenitis suppurativa (HS) is a chronic inflammatory disease of follicular occlusion characterized by abscesses, draining sinuses, and scarring. The efficacy and tolerability of combination treatment with oral clindamycin and rifampicin have previously been assessed in 4 studies including groups of Caucasian patients. Overall results are promising with reported improvement rates between 71. Read More

    Acne and hidradenitis suppurativa.
    Br J Dermatol 2018 Jan 30. Epub 2018 Jan 30.
    Department of Dermatology, University Hospital Zurich, Zurich, 8091, Switzerland.
    Acne and hidradenitis suppurativa (HS) both centre on hair follicles. They often occur together as part of the acne tetrad, but are found in distinct localizations. Acne is primarily defined by the presence of comedones and inflammatory lesions. Read More

    Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
    Am J Clin Dermatol 2018 Jan 27. Epub 2018 Jan 27.
    AbbVie Inc., North Chicago, IL, USA.
    Background: Adalimumab is approved for the treatment of hidradenitis suppurativa (HS), plaque psoriasis, and other inflammatory conditions.

    Objective: Our objective was to examine the safety of adalimumab administered every other week (EOW) and every week (EW) in patients with HS and psoriasis and to investigate informative data from non-dermatologic indications.

    Methods: The safety of adalimumab 40-mg EOW versus EW dosing was examined during placebo-controlled and open-label study periods in patients with HS (three studies), psoriasis (two studies), Crohn's disease (six studies), ulcerative colitis (three studies), and rheumatoid arthritis (one study). Read More

    Hidradenitis suppurativa is associated with polycystic ovary syndrome: a population-based analysis in the United States.
    J Invest Dermatol 2018 Jan 26. Epub 2018 Jan 26.
    Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York, USA.
    Polycystic ovary syndrome (PCOS) has been linked to hidradenitis suppurativa (HS). However, evidence establishing a relationship between the two conditions is limited. We sought to determine prevalence of PCOS among HS patients and the strength of the association. Read More

    Incidence of diseases primarily affecting the skin by age group: population-based epidemiologic study in Olmsted County, Minnesota, and comparison with age-specific incidence rates worldwide.
    Int J Dermatol 2018 Jan 29. Epub 2018 Jan 29.
    Division of Clinical Dermatology, Mayo Clinic, Rochester, MN, USA.
    Understanding the effects of age on the epidemiology of diseases primarily affecting the skin is important to the practice of dermatology, both for proper allocation of resources and for optimal patient-centered care. To fully appreciate the effect that age may have on the population-based calculations of incidence of diseases primarily affecting the skin in Olmsted County, Minnesota, and worldwide, we performed a review of all relevant Rochester Epidemiology Project-published data and compared them to similar reports in the worldwide English literature. Using the Rochester Epidemiology Project, population-based epidemiologic studies have been performed to estimate the incidence of specific skin diseases over the past 50 years. Read More

    Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 2.
    Australas J Dermatol 2018 Jan 23. Epub 2018 Jan 23.
    Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.
    Hidradenitis suppurativa is a chronic, painful, autoinflammatory condition resulting in nodules, abscesses and sinus tracts. We present an evidence-based review providing new understanding of the pathogenesis of hidradenitis suppurativa and associated comorbidities. By the nature of their speciality, dermatologists are uniquely positioned to investigate and treat patients. Read More

    Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease.
    Dig Dis Sci 2018 Mar 22;63(3):755-760. Epub 2018 Jan 22.
    PRA Health Sciences, 4130 Parklake Ave, Suite 400, Raleigh, NC, 27612, USA.
    Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder characterized by recurrent nodules, abscesses, and sinus tracts that can be debilitating and significantly impair quality of life. Small studies and case reports have suggested a possible association between HS and inflammatory bowel disease (IBD).

    Aims: We performed a case-control study to further characterize IBD patients with HS in terms of smoking status, BMI, sites affected by HS, IBD type and features, and IBD medication history. Read More

    Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1.
    Australas J Dermatol 2018 Jan 21. Epub 2018 Jan 21.
    Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.
    Hidradenitis suppurativa is a chronic, painful, autoinflammatory condition resulting in nodules, abscesses and sinus tracts. We present an evidence-based review providing new understanding of the pathogenesis of hidradenitis suppurativa and associated comorbidities. By the nature of their speciality, dermatologists are uniquely positioned to investigate and treat patients with this condition. Read More

    Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa.
    J Clin Aesthet Dermatol 2017 Sep 1;10(9):36-38. Epub 2017 Sep 1.
    All authors are with the University of North Carolina at Chapel Hill, Dermatology, in Chapel Hill, North Carolina.
    Pyoderma gangrenosum and hidradenitis suppurativa are skin conditions characterized by an intense neutrophil-mediated inflammatory response that is often difficult to effectively treat. Successful use of interleukin (IL)-1β inhibition using canakinumab and anakinra has been reported in patients with concomitant pyoderma gangrenosum and hidradenitis suppurativa. We report two cases where targeted therapy with canakinumab failed to lead to improvement for patients with pyoderma gangrenosum and hidradenitis suppurativa. Read More

    Prevalence of Type II Diabetes Mellitus Among Patients with Hidradenitis Suppurativa in the United States.
    J Am Acad Dermatol 2018 Jan 12. Epub 2018 Jan 12.
    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY. Electronic address:
    Background: Few studies have evaluated the relationship between hidradenitis suppurativa (HS) and diabetes mellitus (DM), and the existing data show conflicting results.

    Objective: To determine prevalence of DM among HS patients, and identify at risk demographic subgroups.

    Methods: Cross-sectional analysis identifying DM among HS and non-HS patients from a demographically heterogeneous population-based sample of over 50 million patients in the United States. Read More

    The immunological disease continuum of inflammation against self as an explanation for the lack of association between hidradenitis suppurativa and autoimmune thyroid disease.
    Clin Exp Dermatol 2018 Jan 12. Epub 2018 Jan 12.
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals, Leeds, UK.

    Prevalence of positive QuantiFERON gold in-tube testing in hidradenitis suppurativa.
    J Dermatolog Treat 2018 Jan 22:1-4. Epub 2018 Jan 22.
    a Division of Rheumatology, Ideas to Health Laboratory , The George Washington University, School of Medicine and Health Sciences , Washington , DC , USA.
    Aim: Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory disease of the apocrine sweat glands. Tumor necrosis factor-alpha (TNF-α) inhibitors are commonly used to treat HS. However, prior to initiating therapy patients must be screened for mycobacterium tuberculosis (mTB) exposure. Read More

    [Surgical treatment options for hidradenitis suppurativa/acne inversa].
    Hautarzt 2018 Feb;69(2):149-161
    Klinik für Dermatologie, Venerologie und Allergologie, St. Josef-Hospital, Klinik der Ruhr-Universität Bochum, Gudrunstr. 56, 44791, Bochum, Deutschland.
    Hidradenitis suppurativa/acne inversa (HS/AI) is a chronic inflammatory skin disease. Therapy consists of conservative and surgical treatment options. In Hurley stages II and III, surgical intervention is regarded as the method of choice for areas with irreversible tissue destruction. Read More

    Carotid ultrasound is useful for the cardiovascular risk stratification in patients with hidradenitis suppurativa.
    PLoS One 2018 4;13(1):e0190568. Epub 2018 Jan 4.
    Division of Internal Medicine. Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Cantabria, Spain.
    Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disease which has been associated with an increased risk of adverse cardiovascular (CV) outcomes. Adequate stratification of the CV risk is an issue of major importance in patients with HS. To analyze the usefulness of carotid ultrasound (US) assessment for the CV disease risk stratification compared with a traditional score, the Framingham risk score (FRS), in a series of patients with HS. Read More

    Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
    Cytokine 2018 Mar 28;103:20-24. Epub 2017 Dec 28.
    Unidad de Gestión Clínica de Dermatología, Hospital Universitario Puerta del Mar, Cádiz, Spain.
    Background: T-helper (Th)-17 lymphocytes and neutrophils are the main sources of the proinflammatory cytokines involved in the pathogenesis of hidradenitis suppurativa (HS).

    Objectives: This study aims to evaluate the improvement of the inflammatory serum markers (ISM) levels in patients with moderate-to-severe HS who receive adalimumab.

    Methods: Nineteen moderate-to-severe HS patients were prospectively recruited. Read More

    Men, main victims of hidradenitis suppurativa (A prospective cohort study).
    Int J Surg 2018 Feb 25;50:6-10. Epub 2017 Dec 25.
    Department of Surgery, Faculty of Medicine, University of Medical Sciences of Tabriz, Iran.
    Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease presenting as painful subcutaneous nodules, characterized by multiple abscess, inter-networking sinus tracts. We present the option of surgical treatment involving wide surgical excision and methods of reconstruction as well as the rate of recurrence.

    Method: This study reviewed 44 sites in 21 patients with moderate to extensive HS treated surgically in our hospital from 2000 to 2016, with a follow up of at least 24 months. Read More

    Novel POFUT1 mutation associated with hidradenitis suppurativa-Dowling-Degos disease firm up a role for Notch signalling in the pathogenesis of this disorder.
    Br J Dermatol 2017 Dec 23. Epub 2017 Dec 23.
    Department of Dermatology, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain.

    Novel POFUT1 mutation associated with hidradenitis suppurativa-Dowling Degos Disease firm up a role for Notch signalling in the pathogenesis of this disorder: reply from authors.
    Br J Dermatol 2017 Dec 22. Epub 2017 Dec 22.
    Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
    We thank González-Villanueva et al. for their comments and commend them for their intriguing results. They report on a single patient with clinical and histopathological evidence for Dowling-Degos disease. Read More

    Hidradenitis suppurativa treated with wide excision and second intention healing: a meaningful local cure rate after 253 procedures.
    J Eur Acad Dermatol Venereol 2017 Dec 19. Epub 2017 Dec 19.
    Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
    Background: Surgery is an important treatment modality for hidradenitis suppurativa (HS). Various methods of HS surgery have been described. Even though wide excision is a common surgical procedure for HS, data on the recurrence rate and patient satisfaction are scarce. Read More

    [What's new in dermatological treatment?]
    Ann Dermatol Venereol 2017 Dec;144 Suppl 4:IVS47-IVS53
    Service de dermatologie, hôpital Robert-Debré, Reims, France. Electronic address:
    On a therapeutic point of view, 2017 in dermatology could be summarized in one disease, one pathway and in one number : atopic dermatitis, JAK inhibitors and 23. 2017 will be the year of the first registration of a biologic treatment in atopic dermatitis, dupilumab, with numerous other drugs currently in development. JAK inhibitors show promising results in several difficult-to-treat conditions, such as alopecia areata, vitiligo or atopic dermatitis, but still warrant confirmation in upcoming controlled trials. Read More

    [What's new in instrumental dermatology?]
    Ann Dermatol Venereol 2017 Dec;144 Suppl 4:IVS10-IVS15
    Service de dermatologie générale et oncologique, CHU Ambroise-Paré 9, avenue Charles-de-Gaulle, 92200 Boulogne-Billancourt, 75007 Paris, France; cabinet médical, 4 bis, avenue de Ségur, 75007 Paris, France. Electronic address:
    This "What's new in instrumental dermatology" dedicated skin surgeryis based upon a 2015-2017 literature analysis. The excision of skin cancers is an important part of surgical dermatology. Will artificial intelligence and new drug be able to face the increasing need for therapy? Wrong-site surgery is due to multiple factors. Read More

    Miscellaneous skin disease and the metabolic syndrome.
    Clin Dermatol 2018 Jan - Feb;36(1):94-100. Epub 2017 Sep 8.
    Department of Dermatology, Istanbul Medeniyet University, Medical School, Istanbul, Turkey. Electronic address:
    The link between the metabolic syndrome (MetS) and skin diseases is increasingly important, with new associations being discovered. The association between MetS and psoriasis or MetS and hidradenitis suppurativa is well known, although the relationship between MetS and various autoimmune or inflammatory diseases has only recently attracted interest. Some inflammatory skin diseases, such as vitiligo, scleredema, recurrent aphthous stomatitis, Behçet disease, rosacea, necrobiosis lipoidica, granuloma annulare, skin tags, knuckle pads, and eruptive xanthomas, have possible associations with MetS. Read More

    Genetics and the metabolic syndrome.
    Clin Dermatol 2018 Jan - Feb;36(1):9-13. Epub 2017 Sep 8.
    Department of Endocrinology, St Vincent's University Hospital, University College Dublin, Dublin, Ireland. Electronic address:
    Originally coined as "syndrome X" in 1988 by Gerald Reaven (1928), the metabolic syndrome (MetS) encompasses a constellation of risk factors, the coincidence of which amounts to an increased cardiovascular and diabetic risk. Rising numbers of dermatoses are being recognized as cutaneous markers of MetS. Dermatologists should look beyond treating the cutaneous condition and quantify the associated increase in cardiovascular risk. Read More

    Cutaneous manifestations of obesity and themetabolic syndrome.
    Clin Dermatol 2018 Jan - Feb;36(1):81-88. Epub 2017 Sep 8.
    Department of Dermatology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey.
    The cutaneous manifestations of obesity and the associated metabolic syndrome (MetS) may present with a wide variety of cutaneous findings, including acanthosis nigricans, acrochordon, cellulitis, psoriasis, hidradenitis suppurativa, acne, and hirsutism. Being aware of such clinical signs and the underlying systemic disorders may facilitate earlier diagnoses, thereby permitting earlier of therapy initiation and prevention of long-term sequelae. In this process, dermatologists are key figures in the early detection of MetS and its clinical manifestations. Read More

    Hidradenitis suppurativa and the metabolic syndrome.
    Clin Dermatol 2018 Jan - Feb;36(1):41-47. Epub 2017 Sep 12.
    Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey. Electronic address:
    The association of the metabolic syndrome (MetS) and its components with immune-mediated chronic inflammatory disorders has attracted much interest within the last two decades. In addition to the well-established association of psoriasis with MetS, recent data point to an association between MetS and hidradenitis suppurativa, as well. The association of hidradenitis suppurativa with MetS and its components, such as diabetes, obesity, and dyslipidemia, has been consistently identified in controlled studies. Read More

    1 OF 36